TTC9C

Across TCGA pan-cancer cohorts, TTC9C mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TTC9C data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TTC9C mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TTC9C expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where TTC9C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.808	1.000	.003	31	view →
COAD	DFS	Median	II,III,IV	0.876	1.000	.015	30	view →
PDAC	DFS	Quartile	III,IV	0.757	0.203	.026	3	view →
LUAD	OS	Tertile	II,III,IV	0.827	0.472	.019	3	view →
LSCC	DFS	Median	All	0.842	0.635	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TTC9C–CCRCC (OS)

Open the CCRCC breakdown →